AI: DeepSeek (deepseek-chat)

Q: {
  "guidelineId": "cg1195-anti-d-guideline-pdf",
  "fieldsProcessed": [
    "humanFriendlyName",
    "organisation",
    "yearProduced",
    "summary"
  ],
  "enhancedFields": 4,
  "contentLength": 3490
}

A: {
  "success": true,
  "enhancedFields": [
    {
      "field": "humanFriendlyName",
      "oldValue": null,
      "newValue": "Guidelines for Anti-D Administration in RhD-Negative Pregnant Women",
      "action": "added"
    },
    {
      "field": "organisation",
      "oldValue": null,
      "newValue": "RCOG",
      "action": "added"
    },
    {
      "field": "yearProduced",
      "oldValue": null,
      "newValue": "The text provided does not contain a publication year. If you have another guideline text that includes the year, please share it, and I can extract the 4-digit year for you",
      "action": "added"
    },
    {
      "field": "summary",
      "oldValue": null,
      "newValue": "**Summary of Guideline on Anti-D Administration for RhD-Negative Pregnant Women:** - **Purpose:** Prevent RhD sensitization and Haemolytic Disease of the Fetus and Newborn (HDFN) via targeted Anti-D administration. - **Testing:** Cell-free DNA fetal D testing identifies RhD-positive fetuses, allowing selective Anti-D prophylaxis. - **Administration:** Anti-D (1500IU) should be given within 72 hours of sensitizing events (e.g., delivery, bleeding, procedures) or as routine prophylaxis if cfDNA testing is declined/failed. - **Documentation:** Record on electronic prescription charts and Maternity Information System; monitor for allergic reactions. - **Special Cases:** IV/subcutaneous Anti-D for severe thrombocytopenia/bleeding disorders. - **Birth Management:** Cord blood/Kleihauer testing post-delivery; additional Anti-D if fetal-maternal hemorrhage (FMH) >4mL. - **Follow-Up:** Missed doses require DATIX reporting, SHOT notification, and antibody testing at 6 months postpartum. - **Monitoring:** Deviations tracked via DATIX and Patient Blood Management Committee. **Pathways:** - **Pathway 1:** cfDNA testing with consent. - **Pathway 2:** Routine Anti-D prophylaxis if cfDNA testing is unsuccessful or fetus is D-positive. **Key Points:** Universal precautions for blood products, strict timing for Anti-D, and structured follow-up for sensitization risks",
      "action": "added"
    }
  ]
}